bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
20 Dicembre 2023 - 3:41AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced
the pricing of its underwritten public offering of 83,333,333
shares of its common stock at a public offering price of $1.50 per
share, before deducting underwriting discounts and commissions.
bluebird also granted the underwriters a 30-day option to purchase
up to an additional 12,499,999 shares of its common stock at the
public offering price per share, less underwriting discounts and
commissions. The gross proceeds from the public offering are
expected be $125 million, before deducting underwriting discounts
and commissions and offering expenses payable by bluebird and
assuming no exercise of the underwriters’ option to purchase
additional shares of common stock. All shares in the offering are
to be sold by bluebird.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are
acting as joint book running managers for the offering. Raymond
James & Associates, Inc. is acting as co-manager for the
offering.
bluebird intends to use the net proceeds of the offering (i) to
support commercialization and manufacturing for its three approved
gene therapies, ZYNTEGLO, SKYSONA and LYFGENIA; and (ii) to fund
working capital and other general corporate purposes.
The offering is expected to close on or about December 22, 2023,
subject to customary closing conditions.
The offering is being made pursuant to an effective shelf
registration statement on Form S-3, including a prospectus, that
was filed with the U.S. Securities and Exchange Commission (the
“SEC”) on May 9, 2023 and was declared effective by the SEC on May
19, 2023. A preliminary prospectus supplement describing the terms
of the offering has been filed with the SEC. A final prospectus
supplement will be filed with the SEC and will form a part of the
effective registration statement. Copies of the final prospectus
supplement and accompanying prospectus relating to the offering may
be obtained, when available, by contacting Goldman Sachs & Co.
LLC, Attention: Prospectus Department, 200 West Street, New York,
NY 10282, by telephone at (866) 471-2526 or by email at
prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at (866) 803-9204 or by email at
prospectus-eq_fi@jpmorganchase.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or jurisdiction.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Examples of forward-looking statements in this press release
include, without limitation, statements regarding the consummation
of the offering and the anticipated use of the net proceeds from
the offering. All statements that are not statements of historical
facts are, or may be deemed to be, forward-looking statements. Such
forward-looking statements are based on historical performance and
current expectations and projections about our future financial
results, goals, plans and objectives and involve inherent risks,
assumptions and uncertainties, including internal or external
factors that could delay, divert or change any of them in the next
several years, that are difficult to predict, may be beyond our
control and could cause our future financial results, goals, plans
and objectives to differ materially from those expressed in, or
implied by, the statements. No forward-looking statement can be
guaranteed. Forward-looking statements in this press release should
be evaluated together with the many risks and uncertainties that
affect bluebird bio’s business, particularly those identified in
the risk factors discussion in bluebird bio’s Annual Report on Form
10-K, as updated by our subsequent Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and other filings with the Securities
and Exchange Commission. These risks include, but are not limited
to: delays and challenges in our commercialization and
manufacturing of our products; we may encounter additional delays
in the development of our programs, including the imposition of new
clinical holds, that may impact our ability to meet our expected
timelines and increase our costs; the internal and external costs
required for our ongoing and planned activities, and the resulting
impact on expense and use of cash, has been, and may in the future
be, higher than expected which has caused us, and may in the future
cause us to use cash more quickly than we expect or change or
curtail some of our plans or both; substantial doubt exists
regarding our ability to continue as a going concern; our
expectations as to expenses, cash usage and cash needs may prove
not to be correct for other reasons such as changes in plans or
actual events being different than our assumptions; the risk that
the efficacy and safety results from our prior and ongoing clinical
trials will not continue or be seen in additional patients treated
with our product candidates; the risk of insertional oncogenic or
other reportable events associated with lentiviral vector, drug
product, or myeloablation, including the risk of hematologic
malignancy; the risk that any one or more of our products or
product candidates, will not be successfully developed or
commercialized. The forward-looking statements included in this
press release are made only as of the date of this press release
and except as otherwise required by applicable law, bluebird bio
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231219687449/en/
Investors & Media
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
Jess.rowlands@bluebirdbio.com
Grafico Azioni bluebird bio (NASDAQ:BLUE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni bluebird bio (NASDAQ:BLUE)
Storico
Da Mag 2023 a Mag 2024